4.2200 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||4.1600 x 4000|
|Ask||4.2300 x 3200|
|Day's Range||4.0200 - 4.2900|
|52 Week Range||1.8500 - 6.1600|
|Beta (3Y Monthly)||2.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
If you want to know who really controls Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), then you'll have to look at the...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug. The lawsuit alleges that the approval of Ruzurgi, a rival drug from privately held Jacobus Pharmaceutical Co, in May violated provisions of FDA regulations and Catalyst's rights to exclusivity for its drug, Firdapse. For years, patients were able to access the same drug for free from Jacobus, a small, family-run company in New Jersey, through an FDA program called "compassionate use".
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA) and several related parties challenging the recent approval of a new drug application and related drug labeling for Jacobus Pharmaceutical Company’s drug Ruzurgi™ for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in pediatric patients. The complaint was filed today in the United States District Court for the Southern District of Florida.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the Company will be presenting at the Jefferies 2019 Global Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Thursday, June 6 at 10:30 am ET.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has amended its license agreement for Firdapse® to expand its commercial territory. The original license was for North America, and has been amended to include Japan. Upon the achievement of a certain milestone in Japan, Catalyst will have the option to expand the territory further to include most of Asia and Central and South America. “We are pleased to have expanded the scope of our license to include Japan and possibly other territories, as we believe that Japan represents an attractive strategic opportunity for Catalyst,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals, Inc. “The available treatment options for LEMS patients in Japan are very limited and without an approved evidence-based therapy.
Catalyst Pharmaceuticals has ended a legal fight with Northwestern University, according to a recent filing with the U.S. Securities and Exchange Commission. The settlement resolves a patent dispute in which neither company admitted fault, according to Catalyst. The dispute arose from a Aug. 27, 2009, license agreement in which Catalyst tapped Northwestern to develop CPP-115, a drug intended to treat infantile spasms.
Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.
Biotechnology stocks can generate strong opportunities, as they are riddled with catalytic events through the development, regulatory and commercial processes. Catalyst Pharmaceuticals CPRX [NSC] – $3.14 has had an incredibly strong start to the year. After receiving FDA approval for Firdapse back in November of 2018 for adults with Lambert-Eaton Myasthenic Syndrome (LEMS), Catalyst has pleased investors with its commercialization efforts and the potential revenue that the treatment would generate.
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.
Catalyst (CPRX) delivered earnings and revenue surprises of 92.31% and 1045.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed.
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...